Dr. Arthur Suckow, DTx Pharma Inc. – FALCON
One of the first research teams the CMT Research Foundation (CMTRF) funded was DTx Pharma, Inc., and the project focused on delivery of genetic medicine to the myelinating Schwann cells of the peripheral nerves – a major scientific challenge to effectively...
A New Trial for CMT – When Science Moves Quickly
By Keith Fargo, Ph.D., Chief Scientific Officer, CMT Research Foundation The pace of science can seem excruciatingly slow. It can take many years, or even decades, for new ideas to result in clinical trials. Every so often, though, the stars align and a new...Teams at Cyprus Institute of Neurology & Genetics and Nationwide Children’s Hospital Complete CMT Research Foundation-Funded Project, Resulting Therapeutic Now Moving into Pharmaceutical Development
Update, May 17, 2022: This work is now published in The Journal of Clinical Investigation. By Keith Fargo, Ph.D., Chief Scientific Officer, CMT Research Foundation The CMT Research Foundation is pleased to announce that Dr. Kleopas Kleopa, a renowned neuromuscular...CMT Research Foundation funds cutting edge research to deliver therapeutics to the peripheral nervous system
The CMT Research Foundation has awarded nearly $100,000 to support a 13-month project to test a new therapeutic delivery system that may be capable of crossing the blood-nerve barrier and releasing therapeutic payloads to the Schwann cells and axons of the peripheral...DTx Pharma, Inc. Completes CMT Research Foundation-Funded Project
The CMT Research Foundation is pleased to announce that DTx Pharma, Inc. (DTx) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. With funding from the CMT Research Foundation, DTx designed and tested a library of novel...
Important Research News Announcements
- Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot-Marie-Tooth disease May 20, 2023
- TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A May 5, 2023
- DGIST Professor Minseok Kim’s team develops an electronic medicine technology that restores abnormal protein behavior, the cause of Charcot-Marie-Tooth Disease (CMT) March 31, 2023
- Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route towards translation March 25, 2023
- MFN2-dependent recruitment of ATAT1 coordinates mitochondria motility with alpha-tubulin acetylation and is disrupted in CMT2A March 17, 2023
- Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice March 16, 2023
- Restoring Neurofilaments to Axons in a Mouse Model of CMT2E March 1, 2023
- Full-length isoform sequencing for resolving the molecular basis of Charcot-Marie-Tooth 2A February 8, 2023
- Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation February 3, 2023
- Novel Variants in MPV17, PRX, GJB1 , and SACS Cause Charcot-Marie-Tooth and Spastic Ataxia of Charlevoix-Saguenay Type Diseases January 30, 2023